Novartis Says Mylan Infringed Lescol Patent

Law360, New York (February 10, 2011, 7:09 PM EST) -- Novartis Pharmaceuticals Corp. on Tuesday accused Mylan Pharmaceuticals Inc. of infringing a patent covering the anti-cholesterol drug Lescol, less than two weeks after a court rejected Mylan’s bid to make a generic version of the medication.

Novartis alleged in a complaint in the U.S. District Court for the District of Delaware that Mylan’s submission of an abbreviated new drug application to manufacture a Lescol generic violated claims in a Novartis patent for 80 mg sustained-release tablets of the drug.

The patent-in-suit is U.S. Patent Number 6,242,003....
To view the full article, register now.